ArticleUrologic oncology2020
Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults.
Article in Urologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Metabolic syndrome and bladder cancer risk: a comprehensive evidence synthesis combining bibliometric and meta-analysis approaches.BMC urology · 2025Pooled it
- The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2023Pooled it
- The relationship between metabolic syndrome and its components with bladder cancer: a systematic review and meta-analysis of cohort studies.Epidemiology and health · 2022Pooled it
- Bladder cancer patients hospitalized in a medicine ward including three fuo cases following bacillus calmette-guérin immunotherapy.The Canadian journal of urology · 2026Article
- Prognostic value of the triglyceride-glucose index in non-muscle-invasive bladder cancer: a retrospective study.Frontiers in nutrition · 2024Article
- Incidence, prognostic factors and survival in bladder cancer patients: a population-based study.Translational cancer research · 2022Article
- Preoperative Metabolic Syndrome and HDL-C Level Predict the Prognosis of Patients Following Radical Cystectomy: A Propensity Score Matching Study.Frontiers in oncology · 2022Article
- Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis.Frontiers in oncology · 2021Review
- Mutational Landscape and Environmental Effects in Bladder Cancer.International journal of molecular sciences · 2020Review
- Association of obesity and different metabolic status with prognosis in patients with bladder cancer: a retrospective cohort study.Therapeutic advances in urologyArticle
Corrections and comments
- Commented on byGeriatrics.2021
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundNonmuscle-invasive bladder cancer (NMIBC) disproportionately affects older adults who often have coexisting chronic conditions such as metabolic syndrome (MetS). Although prior research suggests that MetS is a risk factor for NMIBC, limited data exists on whether MetS is associated with NMIBC recurrence. Our objective was to evaluate the association between MetS and recurrence in older adults treated for NMIBC.
methodsWe identified 1,485 older (age ≥60 years) NMIBC patients (American Joint Committee on Cancer Stage ≤1) from 2community-based health systems. Using data from the health systems' electronic medical record, MetS was defined as the presence of three of the following: diagnosis codes indicating hypertension, hyperlipidemia, diabetes, or body mass index >30. Follow up time was determined by date of the last follow up in the tumor registry and censored at 10 years. Cox proportional hazards regression of time to recurrence that accounts for the competing risk of death included adjustment for age, sex, smoking status, health system, NMIBC stage/grade, tumor size, and number of specimens with cancer.
resultsOverall, 341 patients (23%) met MetS criteria. Median follow up was 5.9 years and 582 patients (39.2%) died. Patients with MetS were more frequently male (84.2%), and mostly current/former smokers (82.6%). By 10 years, 34.1% of the cohort had experienced a recurrence. After accounting for the competing risk of death, there was no association between MetS and time to recurrence (adjusted hazard ratio, 0.88, 95% confidence interval 0.70-1.11, P = 0.28). Patients without MetS had more 0a/low grade recurrences (49.1% vs. 41.4%), though differences were not significant.
conclusionWe found no association between MetS and risk of NMIBC recurrence in this large, multisite cohort of older adults with NMIBC. In order to design personalized care for older NMIBC patients, future research is needed to evaluate associations between common chronic conditions and a variety of oncologic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.